Cargando…
Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer
Integrating immunotherapy, proton therapy and biological dose escalation into the definitive chemoradiation of oropharyngeal cancer poses several challenges. Reliable and reproducible data must be obtained in a timely fashion. However, despite recent international radiotherapy contouring guidelines,...
Autores principales: | Cristaudo, Agostino, Hickman, Mitchell, Fong, Charles, Sanghera, Paul, Hartley, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163293/ https://www.ncbi.nlm.nih.gov/pubmed/29954154 http://dx.doi.org/10.3390/medicines5030065 |
Ejemplares similares
-
Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial
por: Vreugdenhil, M., et al.
Publicado: (2021) -
A prospective comparison of common toxicity criteria adverse events Version 3 and 4 in assessing oral mucositis for oral and oropharyngeal carcinoma
por: Hickman, M., et al.
Publicado: (2017) -
Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients
por: Mowry, Sarah E., et al.
Publicado: (2009) -
A Dosimetric Comparison of Primary Chemoradiation Versus Postoperative Radiation for Locally Advanced Oropharyngeal Cancer
por: Woo, Stanley K, et al.
Publicado: (2017) -
A predictive model for advanced oropharyngeal cancer patients treated with chemoradiation
por: Lo, Wu-Chia, et al.
Publicado: (2022)